GlassScriptPhysician profile
Kendall Sheffield
NPI 1104653948
$1,475.22
in general payments reported to CMS, 2019-2025
16 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $158 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $514.45 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $227.37 | 2024-2025 | Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $97.83 | 2024-2025 | Gemtesa |
| Amgen INC. | $91.58 | 2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $74.78 | 2025 | Trelegy Ellipta |
| Lilly USA, LLC | $58.13 | 2025 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $53.30 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.98 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $48.09 | 2025 | Rexulti |
| Abbvie INC. | $46.98 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.38 | 2024-2025 | Xifaxan |
| Eisai INC. | $41.69 | 2024 | |
| Pfizer INC. | $39.75 | 2025 | |
| Shield Therapeutics INC | $38.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.86 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $14.48 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Sheffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.